Vident Advisory’s AstraZeneca AZN Stock Holding History

Vident Advisory’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$5.53M	Buy	28,032 +3,236	+13%	+$624K	0.05%	330
2025 Q4	$4.56M	Sell	24,796 -901	-4%	-$158K	0.04%	353
2025 Q3	$3.94M	Buy	25,697 +598	+2%	+$90.5K	0.04%	367
2025 Q2	$3.51M	Sell	25,099 -23,491	-48%	-$3.29M	0.04%	356
2025 Q1	$7.14M	Buy	48,590 +31,800	+189%	+$4.6M	0.1%	181
2024 Q4	$2.2M	Sell	16,790 -760	-4%	-$106K	0.04%	390
2024 Q3	$2.73M	Buy	17,550 +2,582	+17%	+$417K	0.07%	311
2024 Q2	$2.33M	Buy	14,968 +4,206	+39%	+$633K	0.06%	316
2024 Q1	$1.46M	Sell	10,762 -315	-3%	-$41.7K	0.03%	468
2023 Q4	$1.49M	Buy	11,077 +224	+2%	+$29.1K	0.04%	454
2023 Q3	$1.47M	Buy	+10,853	New	+$1.48M	0.05%	401

Other funds holding AZN

Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

VAM

Vanguard Asset Management London, Ec4n 8af $117B AUM

Vident Advisory's AZN Position: Q1 2026 in Review

Vident Advisory increased its AstraZeneca (AZN) stake by 13% in Q1 2026, buying an estimated $624K and bringing the position to 28,032 shares worth $5.53M. The position accounts for 0.05% of the portfolio, ranked #330.

Vident Advisory first reported a position in AZN in Q3 2023 and has held it in 11 quarters since. The position peaked at $7.14M in Q1 2025. 1,377 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

Vident Advisory held 28,032 shares of AstraZeneca worth $5.53M as of Q1 2026.
Vident Advisory bought 3,236 AstraZeneca shares in Q1 2026, an estimated $624K.
AstraZeneca made up 0.05% of Vident Advisory's portfolio in Q1 2026, its #330 holding.
Vident Advisory first reported a position in AstraZeneca in Q3 2023 and has held it in 11 quarters since.
Vident Advisory's AstraZeneca position peaked at $7.14M in Q1 2025.
1,377 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on Vident Advisory's 13F filing for Q1 2026, filed 15 May 2026.